DVAX Dynavax Technologies Corporatio

5.55
+0.00  (0%)
Previous Close 5.55
Open 5.60
Price To book 2.59
Market Cap 270.80M
Shares 48,793,000
Volume 194,982
Short Ratio 3.14
Av. Daily Volume 1,306,990

SEC filingsSee all SEC filings

  1. 8-K - Current report 17870063
  2. 8-K - Current report 17822926
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822824
  4. EFFECT - Notice of Effectiveness 17786018
  5. CORRESP [Cover] - Correspondence

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 1Q 2017.
SD-101
Head and neck squamous-cell carcinoma cancer
Phase 1b/2 poster at ASCO June 3, 2017. Abstract 9550.
SD-101 + Pembrolizumab
Melanoma - cancer
Phase 1/2 data presented at ASH 2016.
SD-101
Low-grade, B cell lymphoma
CRL February 25, 2013 and November 14, 2016. New PDUFA August 10, 2017. Advisory Committee Meeting July 28, 2017.
HEPLISAV-B
Hepatitis B
Phase 2 enrolling as of early 2017.
AZD1419
Asthma

Latest News

  1. Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  2. ETFs with exposure to Dynavax Technologies Corp. : May 11, 2017
  3. Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  4. Dynavax Technologies reports 1Q loss
  5. Dynavax Reports First Quarter 2017 Financial Results
  6. ETFs with exposure to Dynavax Technologies Corp. : April 21, 2017
  7. William Blair Assigns 70% Probability of Approval to Dynavax's Heplisav
  8. What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA
  9. Why Dynavax Technologies Corporation Stock Briefly Spiked Today
  10. Dynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
  11. ETFs with exposure to Dynavax Technologies Corp. : March 27, 2017
  12. Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
  13. Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting
  14. Dynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update
  15. 3 Beaten Down Stocks Ready to Bounce Back
  16. The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
  17. UPDATE: Dynavax shares reverse premarket losses to open flat
  18. Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies

SEC Filings

  1. 8-K - Current report 17870063
  2. 8-K - Current report 17822926
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822824
  4. EFFECT - Notice of Effectiveness 17786018
  5. CORRESP [Cover] - Correspondence
  6. DEF 14A - Other definitive proxy statements 17776265
  7. PRE 14A - Other preliminary proxy statements 17756045
  8. 8-K - Current report 17735070
  9. POS AM - Post-Effective amendments for registration statement 17698469
  10. 8-K - Current report 17685591